Urology Supplements Market Companies
- Biotexlife
- Himalayan Organics
- Himalaya Wellness
- Natrol, LLC.
- Nature's Bounty
- Puritan's Pride
- Schiff Nutrition
- Solaray
- Theralogix
- ZAHLER
Recent News:
- CORONA Remedies, GM, partnered with Ferring Pharmaceuticals in May 2023 to offer India maternal health and urology medicines. The agreement would provide patients in India with innovative medicines, including a few global names, to address unmet therapeutic needs in maternal health and urology.
- The FDA authorized enzalutamide in November 2023 for the treatment of non-metastatic hormone-sensitive prostate cancer. The FDA has approved Enzalutamide (Xtandi) for early use in prostate cancer in nonmetastatic hormone-sensitive patients. Enzalutamide, an androgen receptor signaling inhibitor, can be taken with or without a gonadotropin-releasing hormone (GnRH) agonist in males with biochemical recurrence who are at high risk for metastasis. Enzalutamide is presently the backbone of treatment for metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), and non-metastatic castration-resistant prostate cancer.